drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (autologous CAR T cells)
drug_description
Autologous T cells engineered to express a chimeric antigen receptor targeting CD19 to recognize and kill CD19-positive B-cell lymphoma cells; part of a dual-target CAR T product.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a chimeric antigen receptor that binds CD19 on B cells. CAR engagement activates the T cells via CD3ΞΆ/co-stimulatory signaling, driving proliferation, cytokine release, and perforin/granzyme-mediated cytotoxic killing, resulting in depletion of CD19-positive malignant B cells (and normal B cells).
drug_name
CART-19 autologous CAR T cells
nct_id_drug_ref
NCT06160362